

Jean Schoenen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5509444/publications.pdf>

Version: 2024-02-01

95
papers

6,085
citations

61984

43
h-index

74163

75
g-index

109
all docs

109
docs citations

109
times ranked

5516
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment. <i>Headache</i> , 2022, 62, 65-77.	3.9	10
2	Cluster Headache and the Comprehension Paradox. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 32.	0.6	2
3	Bimodal sensory integration in migraine: A study of the effect of visual stimulation on somatosensory evoked cortical responses. <i>Cephalalgia</i> , 2022, , 033310242210750.	3.9	5
4	Long-Term Effects of Self-Administered Transcranial Direct Current Stimulation in Episodic Migraine Prevention: Results of a Randomized Controlled Trial. <i>Neuromodulation</i> , 2021, 24, 890-898.	0.8	21
5	Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine. <i>Scientific Reports</i> , 2021, 11, 4543.	3.3	25
6	Thalamo-cortical networks in subtypes of migraine with aura patients. <i>Journal of Headache and Pain</i> , 2021, 22, 58.	6.0	12
7	CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. <i>Journal of Headache and Pain</i> , 2021, 22, 128.	6.0	66
8	Old Habits Die Hard: Dietary Habits of Migraine Patients Challenge our Understanding of Dietary Triggers. <i>Frontiers in Neurology</i> , 2021, 12, 748419.	2.4	4
9	Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes. <i>Frontiers in Neurology</i> , 2021, 12, 805334.	2.4	22
10	Headache Related Alterations of Visual Processing in Migraine Patients. <i>Journal of Pain</i> , 2020, 21, 593-602.	1.4	9
11	Interictal Burden of Cluster Headache. <i>Headache</i> , 2020, 60, 360-369.	3.9	30
12	Update on noninvasive neuromodulation for migraine treatment—Vagus nerve stimulation. <i>Progress in Brain Research</i> , 2020, 255, 249-274.	1.4	7
13	Metabolic treatments of migraine. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 295-302.	2.8	13
14	Short-latency afferent inhibition and somato-sensory evoked potentials during the migraine cycle: surrogate markers of a cycling cholinergic thalamo-cortical drive?. <i>Journal of Headache and Pain</i> , 2020, 21, 34.	6.0	13
15	International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020). <i>Frontiers in Human Neuroscience</i> , 2020, 14, 568051.	2.0	143
16	Efficacy and safety of external trigeminal neurostimulation in the prevention of chronic migraine: An open-label trial. <i>Cephalalgia Reports</i> , 2019, 2, 251581631985662.	0.7	6
17	A Randomized Double-Blind, Cross-Over Trial of very Low-Calorie Diet in Overweight Migraine Patients: A Possible Role for Ketones?. <i>Nutrients</i> , 2019, 11, 1742.	4.1	54
18	The EUROLIGHT cluster headache project: Description of methods and the study population — An Internet-based cross-sectional study of people with cluster headache. <i>Cephalalgia Reports</i> , 2019, 2, 251581631986312.	0.7	1

#	ARTICLE	IF	CITATIONS
19	The metabolic face of migraine – from pathophysiology to treatment. <i>Nature Reviews Neurology</i> , 2019, 15, 627-643.	10.1	137
20	Aberrant interactions of cortical networks in chronic migraine. <i>Neurology</i> , 2019, 92, e2550-e2558.	1.1	51
21	Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention. <i>Nutrients</i> , 2019, 11, 811.	4.1	45
22	Increased cerebral responses to salient transitions between alternating stimuli in chronic migraine with medication overuse headache and during migraine attacks. <i>Cephalalgia</i> , 2019, 39, 988-999.	3.9	8
23	Age related metabolic modifications in the migraine brain. <i>Cephalalgia</i> , 2019, 39, 978-987.	3.9	11
24	Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. <i>Cephalalgia</i> , 2019, 39, 3-14.	3.9	122
25	Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: Modelling the serotonin-ovarian hormone interaction in migraine aura. <i>Cephalalgia</i> , 2018, 38, 427-436.	3.9	26
26	Resting state connectivity between default mode network and insula encodes acute migraine headache. <i>Cephalalgia</i> , 2018, 38, 846-854.	3.9	76
27	Increased functional connectivity between the right temporo-parietal junction and the temporal poles in migraine without aura. <i>Cephalalgia Reports</i> , 2018, 1, 251581631880482.	0.7	6
28	Visually induced analgesia during face or limb stimulation in healthy and migraine subjects. <i>Journal of Pain Research</i> , 2018, Volume 11, 1821-1828.	2.0	1
29	Brain Correlates of Single Trial Visual Evoked Potentials in Migraine: More Than Meets the Eye. <i>Frontiers in Neurology</i> , 2018, 9, 393.	2.4	26
30	Evidence of an increased neuronal activation-to-resting glucose uptake ratio in the visual cortex of migraine patients: a study comparing 18FDG-PET and visual evoked potentials. <i>Journal of Headache and Pain</i> , 2018, 19, 49.	6.0	33
31	Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. <i>Journal of Headache and Pain</i> , 2018, 19, 73.	6.0	25
32	Reliability and repeatability of testing visual evoked potential habituation in migraine: A blinded case-control study. <i>Cephalalgia</i> , 2017, 37, 418-422.	3.9	24
33	Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. <i>Cephalalgia</i> , 2017, 37, 423-434.	3.9	110
34	A survey on migraine attack treatment with the CEFALYÂ® device in regular users. <i>Acta Neurologica Belgica</i> , 2017, 117, 547-549.	1.1	14
35	Possible Involvement of the <i>CACNA1E</i> Gene in Migraine: A Search for Single Nucleotide Polymorphism in Different Clinical Phenotypes. <i>Headache</i> , 2017, 57, 1136-1144.	3.9	10
36	Evidence of activation of vagal afferents by non-invasive vagus nerve stimulation: An electrophysiological study in healthy volunteers. <i>Cephalalgia</i> , 2017, 37, 1285-1293.	3.9	83

#	ARTICLE	IF	CITATIONS
37	Heterogeneous incidence and propagation of spreading depolarizations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 1748-1762.	4.3	39
38	Screening for the metabolic syndrome in subjects with migraine. <i>Cephalalgia</i> , 2017, 37, 1180-1188.	3.9	19
39	Functional Changes of the Perigenual Part of the Anterior Cingulate Cortex after External Trigeminal Neurostimulation in Migraine Patients. <i>Frontiers in Neurology</i> , 2017, 8, 282.	2.4	51
40	Sphenopalatine Ganglion Stimulation in Neurovascular Headaches. <i>Progress in Neurological Surgery</i> , 2016, 29, 106-116.	1.3	11
41	Invasive pericranial nerve interventions. <i>Cephalalgia</i> , 2016, 36, 1156-1169.	3.9	14
42	Noninvasive neurostimulation methods for migraine therapy: The available evidence. <i>Cephalalgia</i> , 2016, 36, 1170-1180.	3.9	48
43	Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. <i>Journal of Headache and Pain</i> , 2016, 17, 67.	6.0	47
44	Thalamo-cortical network activity during spontaneous migraine attacks. <i>Neurology</i> , 2016, 87, 2154-2160.	1.1	81
45	Thalamo-cortical network activity between migraine attacks: Insights from MRI-based microstructural and functional resting-state network correlation analysis. <i>Journal of Headache and Pain</i> , 2016, 17, 100.	6.0	68
46	Is there a need for non-drug treatments in headaches?. <i>Cephalalgia</i> , 2016, 36, 1101-1102.	3.9	1
47	Pathophysiological targets for non-pharmacological treatment of migraine. <i>Cephalalgia</i> , 2016, 36, 1103-1111.	3.9	46
48	Hypoxia, a turning point in migraine pathogenesis?. <i>Brain</i> , 2016, 139, 644-647.	7.6	6
49	Lateral inhibition in the somatosensory cortex during and between migraine without aura attacks: Correlations with thalamocortical activity and clinical features. <i>Cephalalgia</i> , 2016, 36, 568-578.	3.9	54
50	Correlation between habituation of visual-evoked potentials and magnetophosphenes thresholds in migraine: A case-control study. <i>Cephalalgia</i> , 2016, 36, 258-264.	3.9	21
51	Visual evoked potentials in subgroups of migraine with aura patients. <i>Journal of Headache and Pain</i> , 2015, 16, 92.	6.0	53
52	O028. Thalamo-cortical network changes during the migraine cycle: insights from MRI-based microstructural and functional resting-state network correlation analysis. <i>Journal of Headache and Pain</i> , 2015, 16, A52.	6.0	2
53	O026. An abnormal transduction of the chromatic stimuli from the outer to the inner retinal layers may contribute to cause photophobia in migraine. <i>Journal of Headache and Pain</i> , 2015, 16, A54.	6.0	1
54	Cerebral responses and role of the prefrontal cortex in conditioned pain modulation: an fMRI study in healthy subjects. <i>Behavioural Brain Research</i> , 2015, 281, 187-198.	2.2	59

#	ARTICLE	IF	CITATIONS
55	Validation of an extended French version of ID Migraine [®] as a migraine-screening tool. <i>Cephalalgia</i> , 2015, 35, 437-442.	3.9	18
56	Targeting pericranial nerve branches to treat migraine: Current approaches and perspectives. <i>Cephalalgia</i> , 2015, 35, 1308-1322.	3.9	26
57	Transcutaneous Supraorbital Nerve Stimulation (t-SNS) with the Cefaly [®] Device for Migraine Prevention: A Review of the Available Data. <i>Pain and Therapy</i> , 2015, 4, 135-147.	3.2	62
58	Stimulation of the sphenopalatine ganglion in intractable cluster headache: Expert consensus on patient selection and standards of care. <i>Cephalalgia</i> , 2014, 34, 1100-1110.	3.9	52
59	Migraine and serotonin: The quest for the Holy Grail goes on. <i>Cephalalgia</i> , 2014, 34, 163-164.	3.9	7
60	Altered processing of sensory stimuli in patients with migraine. <i>Nature Reviews Neurology</i> , 2014, 10, 144-155.	10.1	246
61	Habituation and sensitization in primary headaches. <i>Journal of Headache and Pain</i> , 2013, 14, 65.	6.0	183
62	Genome-wide meta-analysis identifies new susceptibility loci for migraine. <i>Nature Genetics</i> , 2013, 45, 912-917.	21.4	338
63	Migraine prevention with a supraorbital transcutaneous stimulator. <i>Neurology</i> , 2013, 80, 697-704.	1.1	326
64	Lateral inhibition in visual cortex of migraine patients between attacks. <i>Journal of Headache and Pain</i> , 2013, 14, 20.	6.0	77
65	Transcranial Direct Current Stimulation (tDCS) of the visual cortex: a proof-of-concept study based on interictal electrophysiological abnormalities in migraine. <i>Journal of Headache and Pain</i> , 2013, 14, 23.	6.0	96
66	Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. <i>Cephalalgia</i> , 2013, 33, 816-830.	3.9	308
67	Influence of Ovarian Hormones on Cortical Spreading Depression and Its Suppression by L-kynurenine in Rat. <i>PLoS ONE</i> , 2013, 8, e82279.	2.5	19
68	Genome-wide association analysis identifies susceptibility loci for migraine without aura. <i>Nature Genetics</i> , 2012, 44, 777-782.	21.4	294
69	Cortical Excitability in Chronic Migraine. <i>Current Pain and Headache Reports</i> , 2012, 16, 93-100.	2.9	95
70	Intensity dependence of auditory evoked potentials during light interference in migraine. <i>Neuroscience Letters</i> , 2011, 492, 80-83.	2.1	12
71	Is chronic migraine a never-ending migraine attack?. <i>Pain</i> , 2011, 152, 239-240.	4.2	43
72	Headache: spreading from molecules to patients. <i>Lancet Neurology</i> , The, 2010, 9, 11-12.	10.2	0

#	ARTICLE	IF	CITATIONS
73	Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. <i>Nature Genetics</i> , 2010, 42, 869-873.	21.4	332
74	NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. <i>Pharmaceuticals</i> , 2010, 3, 1966-1987.	3.8	50
75	Factors predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. <i>Cephalalgia</i> , 2010, 30, 1290-1295.	3.9	6
76	Neurostimulation therapy in intractable headaches. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2010, 97, 443-450.	1.8	15
77	Habituation and migraine. <i>Neurobiology of Learning and Memory</i> , 2009, 92, 249-259.	1.9	175
78	A Randomized Double-Blind Placebo-Controlled Trial of Thioctic Acid in Migraine Prophylaxis. <i>Headache</i> , 2007, 47, 52-7.	3.9	66
79	Cost estimates of brain disorders in Belgium. <i>Acta Neurologica Belgica</i> , 2006, 106, 208-14.	1.1	11
80	Pain control by vagus nerve stimulation: from animal to man...and back. <i>Acta Neurologica Belgica</i> , 2005, 105, 62-7.	1.1	61
81	Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. <i>Brain</i> , 2004, 128, 98-103.	7.6	189
82	Headache with focal neurological signs or symptoms: a complicated differential diagnosis. <i>Lancet Neurology</i> , The, 2004, 3, 237-245.	10.2	37
83	Repetitive transcranial magnetic stimulation improves open field locomotor recovery after low but not high thoracic spinal cord compression-injury in adult rats. <i>Journal of Neuroscience Research</i> , 2004, 75, 253-261.	2.9	34
84	Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. <i>Clinical Neurophysiology</i> , 2003, 114, 955-972.	1.5	188
85	When Should Triptans be Taken During a Migraine Attack?. <i>CNS Drugs</i> , 2001, 15, 583-587.	5.9	24
86	Subclinical cerebellar impairment in the common types of migraine: A three-dimensional analysis of reaching movements. <i>Annals of Neurology</i> , 2001, 49, 668-672.	5.3	100
87	Subclinical cerebellar impairment in the common types of migraine: A three-dimensional analysis of reaching movements. <i>Annals of Neurology</i> , 2001, 49, 668-672.	5.3	1
88	Peripheral nerve regeneration using bioresorbable macroporous polylactide scaffolds. <i>Journal of Biomedical Materials Research Part B</i> , 2000, 52, 639-651.	3.1	124
89	Prophylactic Treatment of Migraine With beta-Blockers and Riboflavin: Differential Effects on the Intensity Dependence of Auditory Evoked Cortical Potentials. <i>Headache</i> , 2000, 40, 30-35.	3.9	112
90	Eletriptan. <i>CNS Drugs</i> , 1999, 12, 334-335.	5.9	0

#	ARTICLE	IF	CITATIONS
91	Interictal cortical excitability in migraine: A study using transcranial magnetic stimulation of motor and visual cortices. <i>Annals of Neurology</i> , 1998, 44, 209-215.	5.3	202
92	Effects of macrophage transplantation in the injured adult rat spinal cord: A combined immunocytochemical and biochemical study. <i>Journal of Neuroscience Research</i> , 1998, 51, 316-327.	2.9	107
93	Zolmitriptan, a 5-HT _{1B/1D} receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. <i>European Journal of Neurology</i> , 1998, 5, 535-543.	3.3	52
94	Effects of macrophage transplantation in the injured adult rat spinal cord: A combined immunocytochemical and biochemical study. <i>Journal of Neuroscience Research</i> , 1998, 51, 316-327.	2.9	4
95	Contingent negative variation in headache. <i>Annals of Neurology</i> , 1986, 19, 78-80.	5.3	110